The Latest Breaking News from Merck

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Merck's Keytruda scored two important victories in women's cancer, according to presentations Sunday at the ESMO meeting.

Letter signers include Yelp, Snap and Box CEOs, media empire heir James Murdoch, former CEOs of PepsiCo, Lyft and Merck

Merck & Co. has underperformed the healthcare sector this year, but Wall Street analysts are bullish about the stock prospects.

With advancements in biomedical sciences and promising drug pipelines, the healthcare industry is set for substantial growth in the coming years. Hence, investors might find opportunities in adding UnitedHealth Group (UNH), Merck & Co. (MRK), and Pfizer (PFE) to their portfolios for potential gains this year. Read on….

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Merck stock has been struggling since the July 30 earnings announcement and could provide a nice bearish candidate.

These defensive healthcare picks from the Dow Jones Industrial Average are worth a look at current levels for investors seeking passive income.

Despite Merck & Co.’s relative underperformance over the past year, Wall Street analysts remain bullish about the stock’s prospects.